EURneffy® 1 mg Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ?15 kg to <30 kg
California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use
neffy® Approved in China as the First and Only Community Use Epinephrine Product for the Treatment of Allergic Reactions
UPDATE -- ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
ARS Pharmaceuticals Announces Conference Call and Webcast for its Third Quarter 2025 Financial Results
ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology Annual Scientific Meeting
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy®
ARS Pharmaceuticals Secures Up to $250 Million Loan Facility with RA Capital Management and OMERS Life Sciences to Accelerate U.S. Commercialization of neffy®
ARS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Accelerating Growth for neffy®
Pinnacle Hires San Diego Torrey Hills Capital for Investor Relations and Grants Incentive Stock Options
SAGA Metals Achieves 100% Drilling Success in 2025-Reports Final Assays from Trapper South at Radar Critical Minerals Project in Labrador
